The U.K. drugmaker recently direct-listed its shares in the U.S., betting on a new-drug pipeline to achieve its revenue ...

Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades. He is also the author of the morning Pharmalittle newsletter and ...

Immunogenicity dragged on the efficacy of AstraZeneca’s rare endocrine disorder prospect in a phase 3 trial, causing the $800 ...

The advisory panel wasn't convinced that a clinical trial proved that early switching to camizestrant improved long-term ...

Sir Kier Starmer announces the multi-million-pound investment in the House of Commons.

AstraZeneca is the latest Big Pharma company looking to tap into agentic artificial intelligence (AI), inking a three-year ...

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...

Pharmaceutical company AstraZeneca on Tuesday said it planned to increase its total revenue to $80 billion by 2030 — up 75% from $45.8 billion in 2023. AstraZeneca said it will focus on its oncology, ...

AstraZeneca’s AI strategy has moved well past the exploration phase as upskilling employees became a priority. The ...

AstraZeneca has today beaten first-quarter sales and profit expectations and maintained its 2026 outlook, as demand for its cancer drugs and investments in key markets helped the drugmaker navigate a ...

After a quarter in which sales topped $15 billion and key readouts went AstraZeneca’s way, the company is increasingly ...

Top 10 foreign healthcare stocks by Seeking Alpha Quant Ratings—see high-conviction pharma/biotech picks like JAZZ and AZN, ...